Media Thread, page-2291

Not a good review
Imugene (ASX:IMU)

Shane Fitzgerald (SELL): Imugene for us is a sell. It's got a very novel modality it's going down for its solutions, it's drugs. However, it's a very early stage business. Only one of its drugs is in stage two clinical trials, the others are in stage one, even preclinical really. So for that valuation, given there's so much road still ahead of this business, we think it's pretty full at the moment, so we would say it's a sell.

James Marlay: Emanuel, cancer therapies, obviously a huge and very attractive market. Attractive to the directors, that bought some shares a little bit earlier on this year. Are you buying with the directors or are you a hold or a sell?

Emanuel Datt (SELL): I'm a sell as well, James. I think Shane hits the nail on the head when he says that this is an early-stage drug company. And I think investors have to keep in mind that drug development is a risky process. Only about 10% of drugs actually progress all the way through the whole clinical trial phase through to regulatory approval. And I think at over a billion dollars in market cap, it's very expensive for us.